Common Drug Review 1					
Canadian Agency for Drugs and Technologies	Submission Status				
in Health Product:	Aubagio				
Generic Name:	teriflunomide				
Manufacturer:	Genzyme Canada				
Indication:	Multiple sclerosis, relapsing				
Submission Type:	Pre-NOC - Initi	al			
Date Submission Received:	2013-Aug-28 Date NOC Issued: 2013-Nov-14				
Orginal Targeted CDEC Meeting:	2013-Feb-19	Priority Review Granted:		Not Requested	
Phase	Target Time (Business Days)	Target Date <sup>2</sup>	Actual CDR Date	Comments	S
Submission deemed complete	5	2013-Sep-05	2013-Sep-05	<ul> <li>Submission placed in queue in accordance with CDR procedures. Review to be initiated pending availability of resources and target dates will be updated.</li> <li>Review has been initiated 2014-Jan-08</li> </ul>	
Patient group input submission received <sup>3</sup>		2013-Sep-20	2013-Sep-20	<ul> <li>Call for patient input posted on 2013-Aug-28</li> <li>Patient input deadline: 2013-Sep-20</li> <li>Patient input submission received</li> </ul>	
Patient group input summary comments received	5	2014-Jan-21	2014-Jan-21	<ul> <li>Patient input summary sent for review on 2014-Jan-14</li> <li>Patient input summary feedback deadline: 2014-Jan-21</li> <li>Patient input summary feedback received</li> </ul>	
CDR review reports sent to manufacturer <sup>4</sup>	45	2013-Nov-20	2014-Apr-01	- New target date: 2014-Mar-24 - New target date: 2014-Apr-01	
Comments from manufacturer on CDR review reports received by CADTH	7	2013-Nov-29	2014-Apr-10	- New target date: 2014-Apr-02 - New target date: 2014-Apr-10	
Redaction response from manufacturer on CDR review reports received by CADTH	3	2013-Dec-04	2014-Apr-15	- New target date: 2014-Apr-07 - New target date: 2014-Apr-15	
CDEC meeting		2013-Feb-19	2014-May-21	- New target date: 2014-May-21	
CDEC recommendation & redacted CDR review reports sent to drug plans and manufacturer	5 to 7	2013-Feb-26	2014-May-28	- New target date: 2014-May-28	
Embargo period and validation of redacted CDR review reports <sup>5</sup> Manufacturers may make a request for reconsideration and drug plans may make a request for clarification of the recommendation	10	2013-Mar-12	2014-Jun-11	- New target date: 2014-Jun-11	
Final recommendation sent to drug plans and manufacturer (No requests for clarification are made AND no request for reconsideration is made or request for reconsideration is resolved)	5	2013-Mar-19	2014-Jun-18	- New target date: 2014-Jun-18 - Notice of final recommendation issued	
CDEC final recommendation posted <sup>6</sup>	variable		2014-Jun-20		
Final CDR review reports posted 7	variable		2014-Oct-08		
OR					
Clarification and final recommendation sent to drug plans and manufacturer (Clarification requested, no request for reconsideration made)	5				
CDEC final recommendation posted <sup>6</sup>	variable				
Final CDR review reports posted <sup>7</sup>	variable				
OR					
Placed on CDEC agenda for reconsideration (At manufacturer's request)	25 Depends on Meeting Dates				
Final recommendation sent to drug plans and manufacturer	5				
CDEC final recommendation posted <sup>6</sup>	variable				
Final CDR review reports posted <sup>7</sup>	variable				

<sup>1</sup> Refer to the Procedure for Common Drug Review on the Common Drug Review section of <u>www.cadth.ca</u> for more details.

<sup>2</sup> The target dates for this report are based on the CDEC meeting schedule, which is posted on www.cadth.ca.

<sup>4</sup> Target time is calculated, based on the date the Reviewers receive copies of the Manufacturer's Submission. Target time does not include the time allocated for receipt of Manufacturer's binders (5 business days) and time allocated for distribution of binders to reviewers (3 business days).

<sup>5</sup> The Recommendation is held in confidence by all stakeholders and not acted upon until after CADTH has issued the notice of Final Recommendation.

<sup>6</sup> The target date for posting the CDEC final recommendation depends on several factors including the need for consultation with the manufacturer regarding redaction issues.

<sup>7</sup> The timing of the posting of CDR review reports depends on several factors, including the need for consultation with the manufacturer in case of disagreement with regard to redactions made.

This Submission Status Report reflects status as of Thursday noon.

<sup>&</sup>lt;sup>3</sup> The deadline for Patient Group Input is 15 business days after CADTH receives the Submission or up to 25 business days if advance notice of a Submission is received from the Manufacturer.